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Scientific comment
Comment on “Influence of βS-globin haplotypes and 
hydroxyurea on tumor necrosis factor-alpha levels in sickle 
cell anemia”
Lidiane de Souza Torres*
Universidade Estadual Paulista (UNESP), São José do Rio Preto, SP, Brazil
Sickle cell anemia (SCA) is a monogenic disorder characterized 
by homozygous inheritance of an abnormal hemoglobin 
molecule, hemoglobin S (Hb S), due to the substitution of 
glutamic acid for valine at position 6 of the beta globin 
chain.1,2 SCA is characterized by a variable clinical course and 
differences in response to medication, reflecting its complex 
pathophysiology and suggesting that it can be affected by 
modulator factors such as the haplotypes of the beta globin 
chain or fetal hemoglobin (Hb F) levels.3,4
The pathogenesis of SCA derives primarily from the 
polymerization of deoxygenated Hb S in red blood cells, 
leading to their deformability and rigidity. This sickling 
process, in turn, results in two primary pathological 
events: vaso-occlusion mediated by ischemia-reperfusion 
injury and hemolytic anemia. Both of these are thought to 
increase vascular inflammation, due to the numerous pro-
inflammatory proteins in circulation playing a fundamental 
role in the activation of endothelial cells and leucocytes.5,6
In addition to an activated endothelium and leukocytosis, 
the inflammatory phenotype of SCA is characterized by high 
levels of acute-phase proteins and cytokines. SCA patients at 
steady state have chronically elevated levels of tumor necrosis 
factor alpha (TNF-α), interleukins (ILs) such as IL-1b, IL-6 and IL-8, 
C-reactive protein and soluble adhesion molecules. Several cell 
types contribute to the production of inflammatory mediators, 
including activated endothelial cells, leukocytes and platelets.6-8
TNF-α is a member of the TNF superfamily, which is 
composed of 19 ligands and 29 receptors and plays highly 
diversified roles in the body. All members of the TNF 
superfamily, without exception, have an inflammatory role, 
in part, through activation of the transcription factor, nuclear 
factor kappa B (NF-kB). TNF-α is the most important pro-
inflammatory cytokine and is involved in cell growth and 
differentiation, cellular function, activation of endothelial cells 
and leukocytes, macrophage stimulation, affinity of leukocyte 
surface molecules and the survival of many cells.9 Such 
characteristics make TNF-α an important risk factor in SCA.10
Pharmacological induction of Hb F is a potential therapeutic 
strategy for SCA. This is the case of hydroxyurea (HU), it 
increases the total intracellular hemoglobin, γ-globin mRNA 
and Hb F levels. There is also evidence that HU can act as a nitric 
oxide donor and increase cyclic guanosine monophosphate 
(cGMP) levels, which upregulate the translation of the γ globin. 
Therefore, HU increases erythrocyte volume and hemoglobin 
content and decreases the reticulocyte and white blood 
cell counts. The secondary benefits of HU are reduction of 
dehydration, exposure to phosphatidylserine and expression 
of adhesion molecules. All these factors reduce Hb S 
polymerization and make HU an important therapeutic agent 
for the prevention of vaso-occlusion and vasculopathies.11,12
In this edition of the Revista Brasileira de Hematologia e 
Hemoterapia, Laurentino et al. clearly show higher TNF-α 
levels in SCA patients compared to individuals without 
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hemoglobinopathies. Furthermore, the authors noted that 
the Bantu haplotype substantially influences the levels of 
this cytokine, elevating its plasma concentration. However, no 
difference was found regarding HU treatment.13
As previously reported by the same research group14 and 
by other studies,15-17 TNF-α levels are increased in SCA. This 
important finding supports the association between pro-
inflammatory cytokine release and the clinical severity of 
SCA as these cytokines induce adhesion molecule activity in 
the endothelium.18 Moreover, Laurentino et al. found higher 
TNF-α levels in individuals with the Bantu haplotype than 
those with the Benin haplotype.13 These data not only reflect 
the severity of the disease but also the effect of haplotypes in 
modulating the SCA phenotype. The Bantu haplotype has been 
associated with higher disease severity and high incidence of 
organ, damage while the Benin haplotype is associated with 
an intermediate clinical course.19
Curiously, Laurentino et al. found lower TNF-a levels 
in Bantu/Benin individuals and not with the Benin/Benin 
haplotype.13 This finding leads us to an important question: 
could this be the consequence of bias due to the small sample 
size or do homozygous haplotypes confer a worse clinical 
picture than double heterozygous inheritance? 
Finally, Laurentino et al. did not observe any differences 
between the groups that received HU or not.13 However, some 
studies have demonstrated variations in HU pharmacological 
response according to the βS haplotype, with the Bantu 
haplotype being the most responsive to HU treatment due to a 
significant increase in Hb F levels and reductions in biochemical 
markers of oxidative stress.4,20  Thus, this may mean that the 
difference between the HU treated and untreated groups in this 
study is masked by the inheritance of βS haplotypes.
The current study provides information about the 
inflammatory status in SCA and shows the influence of the 
Bantu haplotype on the clinical course of the disease. It is 
clear that SCA phenotypes are modulated by other genetic 
factors and, therefore, further studies in this area should 
contribute to a better understanding of the disease and the 
treatment of patients.
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